LuPARP
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
- NCT03874884 ↗
- Active, not recruiting
- Peter MacCallum Cancer Centre, Australia
- Deep
We haven't built an HCP commentary report on LuPARP (177Lu-PSMA-617 plus olaparib in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from all 37 indexed sources (Jun 2022 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether olaparib adds benefit over lutetium PSMA alone
- Whether LuPARP warrants larger randomized confirmation
- Whether DNA-repair status should guide selection for the combination
Also discussed: DNA-damage synergy, CTC response tracking, other Lu-PSMA combinations.
Indexed commentary on LuPARP so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 23 | |
| YouTube | 8 | |
| Podcasts | 6 |
The trial
ClinicalTrials.gov- Official title
- 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- Olaparib; 177Lu-PSMA
- Arms
- 177Lu-PSMA + olaparib · Experimental
- Enrollment
- 70 (estimated)
- Primary outcomes
- Dose Limiting toxicities (DLTs)
- Maximum Tolerated dose (MTD)
- Recommended Phase 2 Dose (RP2D)
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Start
- Jul 9, 2019
- Primary completion
- May 2025 (estimated)
- Results posted
- No
- Registry record
- NCT03874884 · updated May 14, 2025
Publications
linked from the registry- Kashyap R, Buteau JP, Bressel M, Eifer M, Bollampally N, Jackson P, McIntosh L, Sandhu S, Hofman MS. Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. J Nucl Med. 2025 Aug 1;66(8):1265-1270. doi: 10.2967/jnumed.125.269640. PubMed 40610228